⌕
Annexon · ANNX · Nasdaq
Tenet 37 · Weak
Compare
$3.47−2.80%At closeTenet 37 · Weak
$3.47−0.10 (−2.80%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Annexon (ANNX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ANNX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 17, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im…

ANNX −2.8% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts  Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q…

ANNX −2.8% todayRead at source ↗
● Defense WorldNov 6, 2026 · 02:17 ET
Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug

Annexon (NASDAQ: ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026. The company is te…

ANNX −2.8% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 18:55 ET
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript

Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript…

ANNX −2.8% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im…

ANNX −2.8% todayRead at source ↗
● GlobeNewsWireOct 16, 2026 · 17:34 ETCOMPANY'S OWN WORDS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that im…

ANNX −2.8% todayRead at source ↗
● Seeking AlphaSep 27, 2026 · 05:50 ET
Annexon: Preserving Patient Function Is The Real Investment Opportunity

Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, su…

ANNX −2.8% todayRead at source ↗
● GlobeNewsWireSep 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demon…

ANNX −2.8% todayRead at source ↗
● GlobeNewsWireSep 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i…

ANNX −2.8% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Annexon to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i…

ANNX −2.8% todayRead at source ↗

No upcoming events in the feeds.

NVDA33−0.4%
DLB4−3.8%
WDAY4−5.8%

Article counts from the last market-wide feed page, across every symbol we track and not just ANNX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.